2 assets in Ureter Squamous Cell Carcinoma

Therapeutic assets addressing Ureter Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Ureter Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Ureter Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)